Toralgen is a preclinical stage biopharmaceutical company focused on the development and commercialization of human therapeutics. Our unique poly-bile nanoparticle platform eliminates the challenges of oral delivery in one simple to fabricate nanopill. These nanopills also localize delivery of drug agents and potentially improve efficacy and safety of a wide range of therapies. Toralgen currently has two candidates in preclinical testing for oral delivery of diabetes agents. Toralgen collaborates with leading pharmaceutical companies to apply our targeted delivery technology across a wide range of therapeutic areas, molecule types and routes of administration.
Visit https://toralgen.com